Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree Of Selection Criteria

NCT02453035 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.

NCT NCT02453035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02453035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree Of Selection Criteria
Lead sponsor
Elixir Medical Corporation
Phase
Observational
Overall status
Terminated
Start date
May 13, 2015
Completion date
April 30, 2017
Enrollment
154 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery stenosis